|
US20030108548A1
(en)
*
|
1993-06-01 |
2003-06-12 |
Bluestone Jeffrey A. |
Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
|
|
US20040002587A1
(en)
*
|
2002-02-20 |
2004-01-01 |
Watkins Jeffry D. |
Fc region variants
|
|
US20080260731A1
(en)
*
|
2002-03-01 |
2008-10-23 |
Bernett Matthew J |
Optimized antibodies that target cd19
|
|
US7662925B2
(en)
*
|
2002-03-01 |
2010-02-16 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
|
US8188231B2
(en)
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
|
US7317091B2
(en)
*
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
|
US20040132101A1
(en)
*
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
US20080254027A1
(en)
*
|
2002-03-01 |
2008-10-16 |
Bernett Matthew J |
Optimized CD5 antibodies and methods of using the same
|
|
US20070148171A1
(en)
*
|
2002-09-27 |
2007-06-28 |
Xencor, Inc. |
Optimized anti-CD30 antibodies
|
|
US8044180B2
(en)
*
|
2002-08-14 |
2011-10-25 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
|
US8193318B2
(en)
*
|
2002-08-14 |
2012-06-05 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
|
US8530627B2
(en)
*
|
2002-08-14 |
2013-09-10 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
|
US8968730B2
(en)
*
|
2002-08-14 |
2015-03-03 |
Macrogenics Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
|
JP4459810B2
(ja)
*
|
2002-08-14 |
2010-04-28 |
マクロジェニクス，インコーポレーテッド |
ＦｃγＲＩＩＢ特異的抗体とその利用法
|
|
US8946387B2
(en)
*
|
2002-08-14 |
2015-02-03 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
|
US8187593B2
(en)
*
|
2002-08-14 |
2012-05-29 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
|
US20060235208A1
(en)
*
|
2002-09-27 |
2006-10-19 |
Xencor, Inc. |
Fc variants with optimized properties
|
|
US7960512B2
(en)
*
|
2003-01-09 |
2011-06-14 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
|
JP2006524039A
(ja)
|
2003-01-09 |
2006-10-26 |
マクロジェニクス，インコーポレーテッド |
変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
|
|
US20070275460A1
(en)
*
|
2003-03-03 |
2007-11-29 |
Xencor.Inc. |
Fc Variants With Optimized Fc Receptor Binding Properties
|
|
US8388955B2
(en)
*
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
|
US8084582B2
(en)
|
2003-03-03 |
2011-12-27 |
Xencor, Inc. |
Optimized anti-CD20 monoclonal antibodies having Fc variants
|
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
|
US9051373B2
(en)
|
2003-05-02 |
2015-06-09 |
Xencor, Inc. |
Optimized Fc variants
|
|
NZ544486A
(en)
*
|
2003-06-13 |
2009-04-30 |
Biogen Idec Inc |
Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof
|
|
EP2502935B1
(en)
|
2003-08-22 |
2017-03-29 |
Biogen MA Inc. |
Improved antibodies having altered effector function and methods for making the same
|
|
US9714282B2
(en)
|
2003-09-26 |
2017-07-25 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
|
US8101720B2
(en)
*
|
2004-10-21 |
2012-01-24 |
Xencor, Inc. |
Immunoglobulin insertions, deletions and substitutions
|
|
GB0324368D0
(en)
*
|
2003-10-17 |
2003-11-19 |
Univ Cambridge Tech |
Polypeptides including modified constant regions
|
|
TR201809892T4
(tr)
*
|
2003-11-05 |
2018-07-23 |
Roche Glycart Ag |
Fc reseptörüne bağlanma afinitesi ve artırılmış efektör fonksiyonu bulunan antijen bağlayan moleküller.
|
|
EP1697520A2
(en)
*
|
2003-12-22 |
2006-09-06 |
Xencor, Inc. |
Fc polypeptides with novel fc ligand binding sites
|
|
EP2053062A1
(en)
*
|
2004-03-24 |
2009-04-29 |
Xencor, Inc. |
Immunoglobin variants outside the Fc region
|
|
US7521542B2
(en)
|
2004-05-10 |
2009-04-21 |
Macrogenics, Inc. |
Humanized FcγRIIB-specific antibodies and methods of use thereof
|
|
US20150010550A1
(en)
|
2004-07-15 |
2015-01-08 |
Xencor, Inc. |
OPTIMIZED Fc VARIANTS
|
|
EA014226B1
(ru)
|
2004-07-26 |
2010-10-29 |
Байоджен Айдек Ма Инк. |
Антитела к cd154, их фрагменты и способы применения антител и фрагментов
|
|
KR20070057839A
(ko)
*
|
2004-08-19 |
2007-06-07 |
제넨테크, 인크. |
변경된 이펙터 기능을 갖는 폴리펩티드 변이체
|
|
WO2006031994A2
(en)
*
|
2004-09-14 |
2006-03-23 |
Xencor, Inc. |
Monomeric immunoglobulin fc domains
|
|
US7632497B2
(en)
*
|
2004-11-10 |
2009-12-15 |
Macrogenics, Inc. |
Engineering Fc Antibody regions to confer effector function
|
|
US20070135620A1
(en)
*
|
2004-11-12 |
2007-06-14 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
CN102746404B
(zh)
|
2004-11-12 |
2016-01-20 |
赞科股份有限公司 |
对FcRn的结合被改变的Fc变体
|
|
US8367805B2
(en)
*
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
US8802820B2
(en)
*
|
2004-11-12 |
2014-08-12 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
US8546543B2
(en)
|
2004-11-12 |
2013-10-01 |
Xencor, Inc. |
Fc variants that extend antibody half-life
|
|
EP1858925A2
(en)
*
|
2005-01-12 |
2007-11-28 |
Xencor, Inc. |
Antibodies and fc fusion proteins with altered immunogenicity
|
|
US20100104564A1
(en)
*
|
2005-03-29 |
2010-04-29 |
Genevieve Hansen |
Altered Antibody Fc Regions and Uses Thereof
|
|
WO2006110593A2
(en)
*
|
2005-04-07 |
2006-10-19 |
Macrogenics, Inc. |
Biological targets for the diagnosis, treatment and prevention of cancer
|
|
US9963510B2
(en)
*
|
2005-04-15 |
2018-05-08 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
|
US9284375B2
(en)
*
|
2005-04-15 |
2016-03-15 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
|
US11254748B2
(en)
|
2005-04-15 |
2022-02-22 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
|
JP5838021B2
(ja)
*
|
2005-04-15 |
2015-12-24 |
マクロジェニクス，インコーポレーテッド |
共有結合型ダイアボディとその使用
|
|
EP1877441A2
(en)
*
|
2005-04-26 |
2008-01-16 |
Bioren, Inc. |
Method of producing human igg antibodies with enhanced effector functions
|
|
US8008443B2
(en)
*
|
2005-04-26 |
2011-08-30 |
Medimmune, Llc |
Modulation of antibody effector function by hinge domain engineering
|
|
EP1899477A4
(en)
*
|
2005-07-01 |
2010-01-20 |
Medimmune Inc |
INTEGRATED APPROACH FOR GENERATING MULTIDOMAIN PROTEIN THERAPEUTIC APPLICATIONS
|
|
WO2007009064A2
(en)
*
|
2005-07-11 |
2007-01-18 |
Macrogenics, Inc. |
Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
|
|
PL1919503T3
(pl)
|
2005-08-10 |
2015-04-30 |
Macrogenics Inc |
Identyfikacja i inżynieria przeciwciał ze zmiennymi regionami FC oraz sposoby ich stosowania
|
|
NO345919B1
(no)
*
|
2005-08-26 |
2021-10-18 |
Roche Glycart Ag |
Modifiserte antigen-bindende molekyler med endret celle-signaliseringsaktivitet
|
|
EP1931709B1
(en)
*
|
2005-10-03 |
2016-12-07 |
Xencor, Inc. |
Fc variants with optimized fc receptor binding properties
|
|
JP4860703B2
(ja)
|
2005-10-06 |
2012-01-25 |
ゼンコー・インコーポレイテッド |
最適化された抗ｃｄ３０抗体
|
|
CN101331223A
(zh)
|
2005-10-14 |
2008-12-24 |
米迪缪尼有限公司 |
细胞展示抗体文库
|
|
CA2644903A1
(en)
*
|
2006-03-10 |
2007-09-20 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant heavy chains and methods of using same
|
|
WO2007108152A1
(ja)
*
|
2006-03-23 |
2007-09-27 |
Tohoku University |
高機能性二重特異性抗体
|
|
ES2489646T3
(es)
*
|
2006-05-26 |
2014-09-02 |
Macrogenics, Inc. |
Anticuerpos humanizados específicos a Fc gamma RIIB y sus métodos de uso
|
|
US9056906B2
(en)
|
2006-06-14 |
2015-06-16 |
Macrogenics, Inc. |
Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
|
|
PT2029173T
(pt)
|
2006-06-26 |
2016-11-02 |
Macrogenics Inc |
Anticorpos específicos fc rib e seus métodos de uso
|
|
WO2008002933A2
(en)
|
2006-06-26 |
2008-01-03 |
Macrogenics, Inc. |
Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
|
|
HRP20140331T1
(hr)
|
2006-08-14 |
2014-05-09 |
Xencor, Inc. |
Optimizirana antitijela usmjerena na cd19
|
|
WO2008030564A2
(en)
*
|
2006-09-08 |
2008-03-13 |
Verenium Corporation |
Aglycosylated antibodies and methods of making and using those antibodies
|
|
JP5562031B2
(ja)
*
|
2006-09-18 |
2014-07-30 |
ゼンコー・インコーポレイテッド |
Ｈｍ１．２４を標的とする最適化抗体
|
|
US20080112961A1
(en)
*
|
2006-10-09 |
2008-05-15 |
Macrogenics, Inc. |
Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same
|
|
US8652466B2
(en)
*
|
2006-12-08 |
2014-02-18 |
Macrogenics, Inc. |
Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
|
|
AU2007337082A1
(en)
*
|
2006-12-21 |
2008-07-03 |
Macrogenics Inc. |
Methods for the treatment of LADA and other adult-onset autoimmune diabetes using immunosuppressive monoclonal antibodies with reduced toxicity
|
|
EP2119780B1
(en)
*
|
2007-01-24 |
2015-03-25 |
Kyowa Hakko Kirin Co., Ltd. |
Genetically recombinant antibody composition having enhanced effector activity
|
|
WO2008118324A2
(en)
|
2007-03-26 |
2008-10-02 |
Macrogenics, Inc. |
Composition and method of treating cancer with an anti-uroplakin ib antibody
|
|
US8629245B2
(en)
*
|
2007-05-01 |
2014-01-14 |
Research Development Foundation |
Immunoglobulin Fc libraries
|
|
US7580304B2
(en)
*
|
2007-06-15 |
2009-08-25 |
United Memories, Inc. |
Multiple bus charge sharing
|
|
MX2009013816A
(es)
|
2007-06-21 |
2010-02-24 |
Macrogenics Inc |
Diacuerpos covalentes y usos de los mismos.
|
|
WO2009151717A2
(en)
|
2008-04-02 |
2009-12-17 |
Macrogenics, Inc. |
Bcr-complex-specific antibodies and methods of using same
|
|
US20110077383A1
(en)
*
|
2007-07-03 |
2011-03-31 |
Medimmune, Llc |
Hinge domain engineering
|
|
PE20140196A1
(es)
|
2007-08-09 |
2014-03-19 |
Boehringer Ingelheim Int |
Anticuerpos anti-cd37
|
|
JP5580205B2
(ja)
|
2007-11-19 |
2014-08-27 |
セレラ コーポレーション |
肺癌マーカーとその使用
|
|
WO2009117030A2
(en)
*
|
2007-12-19 |
2009-09-24 |
Macrogenics, Inc. |
Improved compositions for the prevention and treatment of smallpox
|
|
HRP20150279T1
(hr)
|
2007-12-26 |
2015-05-08 |
Xencor, Inc. |
Fc inaäśice s promijenjenim vezanjem na fcrn
|
|
US12492253B1
(en)
|
2008-02-25 |
2025-12-09 |
Xencor, Inc. |
Anti-human C5 antibodies
|
|
PT2247304T
(pt)
|
2008-04-02 |
2016-08-29 |
Macrogenics Inc |
Anticorpos especificos de her2/neu e métodos de utilização dos mesmos
|
|
CA2726845C
(en)
*
|
2008-06-04 |
2017-09-26 |
Macrogenics, Inc. |
Antibodies with altered binding to fcrn and methods of using same
|
|
BRPI0916072A2
(pt)
*
|
2008-11-17 |
2015-11-10 |
Genentech Inc |
"uso de uma formulação, formulação farmacêutica, usos de um anticorpo 2h7 humanizado, método, método para aumentar a biodisponibilidade de um anticorpo e método de diálise in vitro"
|
|
EP3482769B1
(en)
|
2008-12-19 |
2024-05-29 |
MacroGenics, Inc. |
Covalent diabodies and uses thereof
|
|
TW201031749A
(en)
*
|
2009-02-10 |
2010-09-01 |
Otsuka Chemical Co Ltd |
IgG-Fc fragment and method for manufacturing the same
|
|
WO2010096394A2
(en)
|
2009-02-17 |
2010-08-26 |
Redwood Biosciences, Inc. |
Aldehyde-tagged protein-based drug carriers and methods of use
|
|
DE102009013748B4
(de)
*
|
2009-03-17 |
2012-01-26 |
Paul-Ehrlich-Institut |
Bestimmung von Interaktionen konstanter Antikörperteile mit Fc-gamma Rezeptoren
|
|
EP2711018A1
(en)
*
|
2009-06-22 |
2014-03-26 |
MedImmune, LLC |
Engineered Fc regions for site-specific conjugation
|
|
JP5683581B2
(ja)
*
|
2009-06-30 |
2015-03-11 |
リサーチ ディベロップメント ファウンデーション |
免疫グロブリンＦｃポリペプチド
|
|
WO2011028952A1
(en)
|
2009-09-02 |
2011-03-10 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
TR201804897T4
(tr)
|
2009-10-07 |
2018-06-21 |
Macrogenics Inc |
Fukosi̇lasyon ölçüsünün deği̇şi̇mleri̇nden dolayi geli̇şmi̇ş efektör i̇şlevi̇ sergi̇leyen fc bölgesi̇ni̇ i̇çeren poli̇pepti̇tler ve bunlarin kullanimlarina yöneli̇k yöntemler
|
|
WO2011091078A2
(en)
|
2010-01-19 |
2011-07-28 |
Xencor, Inc. |
Antibody fc variants with enhanced complement activity
|
|
SG10201604336VA
(en)
|
2010-03-04 |
2016-07-28 |
Macrogenics Inc |
Antibodies Reactive With B7-H3, Immunologically Active Fragments Thereof And Uses Thereof
|
|
PH12012501751A1
(en)
|
2010-03-04 |
2012-11-12 |
Macrogenics Inc |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
|
EP2409712A1
(en)
|
2010-07-19 |
2012-01-25 |
International-Drug-Development-Biotech |
Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
|
|
CN103154025B
(zh)
|
2010-08-02 |
2015-07-01 |
宏观基因有限公司 |
共价双抗体及其用途
|
|
WO2012032080A1
(en)
|
2010-09-07 |
2012-03-15 |
F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H |
Stabilised human fc
|
|
NZ607510A
(en)
|
2010-09-10 |
2014-10-31 |
Apexigen Inc |
Anti-il-1 beta antibodies and methods of use
|
|
UA112062C2
(uk)
|
2010-10-04 |
2016-07-25 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
Cd33-зв'язувальний агент
|
|
AU2011325833C1
(en)
|
2010-11-05 |
2017-07-13 |
Zymeworks Bc Inc. |
Stable heterodimeric antibody design with mutations in the Fc domain
|
|
CN103328632A
(zh)
|
2010-11-30 |
2013-09-25 |
中外制药株式会社 |
与多分子的抗原重复结合的抗原结合分子
|
|
WO2012097333A2
(en)
|
2011-01-14 |
2012-07-19 |
Redwood Bioscience, Inc. |
Aldehyde-tagged immunoglobulin polypeptides and method of use thereof
|
|
CN112812184A
(zh)
|
2011-02-25 |
2021-05-18 |
中外制药株式会社 |
FcγRIIb特异性Fc抗体
|
|
MX342810B
(es)
|
2011-03-03 |
2016-10-13 |
Apexigen Inc |
Anticuerpos del receptor anti-interleucina-6 (anti-il-6) y sus metodos de uso.
|
|
WO2012122513A2
(en)
|
2011-03-10 |
2012-09-13 |
Omeros Corporation |
Generation of anti-fn14 monoclonal antibodies by ex-vivo accelerated antibody evolution
|
|
SI2691417T2
(sl)
|
2011-03-29 |
2025-05-30 |
Roche Glycart Ag |
FC variante protitelesa
|
|
ES2669310T3
(es)
|
2011-04-20 |
2018-05-24 |
Medimmune, Llc |
Anticuerpos y otras moléculas que se unen con B7-H1 y PD-1
|
|
JP6152090B2
(ja)
|
2011-04-21 |
2017-06-21 |
ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ |
視神経脊髄炎を処置するための組成物および方法
|
|
EP2702078B1
(en)
|
2011-04-29 |
2018-11-07 |
Apexigen, Inc. |
Anti-cd40 antibodies and methods of use
|
|
JP6145088B2
(ja)
|
2011-05-21 |
2017-06-07 |
マクロジェニクス，インコーポレーテッド |
脱免疫化血清結合ドメイン及び血清半減期を延長するためのその使用
|
|
BR112013029893A2
(pt)
|
2011-05-21 |
2017-05-30 |
Macrogenics Inc |
molécula de ligação a cd3, anticorpo de ligação a cd3, diacorpo de ligação a cd3 e composição farmacêutica
|
|
CN109517059B
(zh)
*
|
2011-06-30 |
2023-03-28 |
中外制药株式会社 |
异源二聚化多肽
|
|
JP5944994B2
(ja)
|
2011-08-12 |
2016-07-05 |
オメロス コーポレーション |
抗ｆｚｄ１０モノクローナル抗体およびそれらの使用方法
|
|
CA2845536A1
(en)
|
2011-08-15 |
2013-02-21 |
Amplimmune, Inc. |
Anti-b7-h4 antibodies and their uses
|
|
TW201817745A
(zh)
|
2011-09-30 |
2018-05-16 |
日商中外製藥股份有限公司 |
具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
|
|
WO2013047748A1
(ja)
|
2011-09-30 |
2013-04-04 |
中外製薬株式会社 |
複数の生理活性を有する抗原の消失を促進する抗原結合分子
|
|
CA2850194C
(en)
*
|
2011-09-30 |
2023-03-21 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule for promoting elimination of antigens
|
|
KR102027603B1
(ko)
|
2011-11-02 |
2019-10-01 |
아펙시젠, 인코포레이티드 |
항-kdr 항체 및 사용 방법
|
|
WO2013063702A1
(en)
|
2011-11-04 |
2013-05-10 |
Zymeworks Inc. |
Stable heterodimeric antibody design with mutations in the fc domain
|
|
KR20230143201A
(ko)
|
2011-11-30 |
2023-10-11 |
추가이 세이야쿠 가부시키가이샤 |
면역 복합체를 형성하는 세포내로의 운반체（캐리어）를 포함하는 의약
|
|
CN104244977A
(zh)
|
2012-02-07 |
2014-12-24 |
先天制药公司 |
Mica结合剂
|
|
EP4624490A3
(en)
|
2012-02-09 |
2025-11-05 |
Chugai Seiyaku Kabushiki Kaisha |
Modified fc region of antibody
|
|
HK1207654A1
(en)
*
|
2012-04-27 |
2016-02-05 |
Bioatla, Llc |
Modified antibody regions and uses thereof
|
|
WO2013169693A1
(en)
|
2012-05-09 |
2013-11-14 |
Bristol-Myers Squibb Company |
Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody
|
|
AU2013258834B2
(en)
|
2012-05-10 |
2017-09-07 |
Zymeworks Bc Inc. |
Heteromultimer constructs of immunoglobulin heavy chains with mutations in the Fc domain
|
|
US11142563B2
(en)
|
2012-06-14 |
2021-10-12 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule containing modified Fc region
|
|
PE20150361A1
(es)
|
2012-07-13 |
2015-03-14 |
Roche Glycart Ag |
Anticuerpos biespecificos anti-vegf/anti-ang-2 y su utilizacion en el tratamiento de enfermedades vasculares oculares
|
|
CN110256559B
(zh)
|
2012-07-25 |
2023-05-26 |
塞尔德克斯医疗公司 |
抗kit抗体及其用途
|
|
WO2014030728A1
(ja)
|
2012-08-24 |
2014-02-27 |
中外製薬株式会社 |
FcγRIIb特異的Fc領域改変体
|
|
CN104918957B
(zh)
|
2012-10-30 |
2018-11-16 |
埃派斯进有限公司 |
抗-cd40抗体及其使用方法
|
|
LT2928923T
(lt)
|
2012-12-10 |
2020-02-25 |
Biogen Ma Inc. |
Anti-kraujo dendritinių ląstelių antigeno 2 antikūnai ir jų panaudojimas
|
|
SG11201504764SA
(en)
|
2012-12-19 |
2015-07-30 |
Amplimmune Inc |
Anti-human b7-h4 antibodies and their uses
|
|
JP6359031B2
(ja)
|
2012-12-21 |
2018-07-18 |
メディミューン，エルエルシー |
抗ｈ７ｃｒ抗体
|
|
DK2940135T5
(da)
|
2012-12-27 |
2021-09-20 |
Chugai Pharmaceutical Co Ltd |
Heterodimeriseret polypeptid
|
|
TWI635098B
(zh)
|
2013-02-01 |
2018-09-11 |
再生元醫藥公司 |
含嵌合恆定區之抗體
|
|
DK2956482T3
(en)
|
2013-02-14 |
2017-10-16 |
Innate Pharma |
TREATMENT OF PERFECT T cell lymphoma
|
|
EP2958941B1
(en)
|
2013-02-20 |
2019-04-10 |
Innate Pharma |
A compound that specifically binds to kir3dl2 for use in the treatment of peripheral t cell lymphoma
|
|
US9487587B2
(en)
|
2013-03-05 |
2016-11-08 |
Macrogenics, Inc. |
Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
|
|
EP2968520B1
(en)
|
2013-03-14 |
2021-05-12 |
MacroGenics, Inc. |
Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor
|
|
US10035860B2
(en)
|
2013-03-15 |
2018-07-31 |
Biogen Ma Inc. |
Anti-alpha V beta 6 antibodies and uses thereof
|
|
WO2014144466A1
(en)
|
2013-03-15 |
2014-09-18 |
Biogen Idec Ma Inc. |
Anti-alpha v beta 6 antibodies and uses thereof
|
|
HK1219740A1
(zh)
|
2013-03-15 |
2017-04-13 |
Biogen Ma Inc. |
使用抗αVβ5抗体治疗和预防急性肾损伤
|
|
KR102049990B1
(ko)
|
2013-03-28 |
2019-12-03 |
삼성전자주식회사 |
c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
|
|
CN113621057A
(zh)
|
2013-04-02 |
2021-11-09 |
中外制药株式会社 |
Fc区变体
|
|
SG11201509618QA
(en)
|
2013-05-24 |
2015-12-30 |
Medimmune Llc |
Anti-b7-h5 antibodies and their uses
|
|
WO2014194293A1
(en)
|
2013-05-30 |
2014-12-04 |
Amplimmune, Inc. |
Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof
|
|
UA116479C2
(uk)
|
2013-08-09 |
2018-03-26 |
Макродженікс, Інк. |
БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
|
|
US11384149B2
(en)
|
2013-08-09 |
2022-07-12 |
Macrogenics, Inc. |
Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
|
|
EP2839842A1
(en)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
|
|
EP2840091A1
(en)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
|
|
US9481729B2
(en)
|
2013-09-11 |
2016-11-01 |
The University Of Hong Kong |
Anti-HER2 and anti-IGF-IR BI-specific antibodies and uses thereof
|
|
PT3702373T
(pt)
|
2013-09-13 |
2022-09-27 |
Beigene Switzerland Gmbh |
Anticorpos anti-pd1 e a sua utilização como agentes terapêuticos e de diagnóstico
|
|
WO2015054039A1
(en)
*
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Fc CONTAINING POLYPEPTIDES HAVING INCREASED BINDING TO FcGammaRIIB
|
|
AU2015217278B2
(en)
|
2014-02-14 |
2020-03-19 |
Macrogenics, Inc. |
Improved methods for the treatment of vascularizing cancers
|
|
GB201403875D0
(en)
|
2014-03-05 |
2014-04-16 |
Cantargia Ab |
Novel antibodies and uses thereof
|
|
SG11201606789SA
(en)
|
2014-03-14 |
2016-09-29 |
Innate Pharma |
Humanized antibodies with increased stability
|
|
TWI701042B
(zh)
|
2014-03-19 |
2020-08-11 |
美商再生元醫藥公司 |
用於腫瘤治療之方法及抗體組成物
|
|
CN106459960A
(zh)
|
2014-05-13 |
2017-02-22 |
生物蛋白有限公司 |
条件活性生物蛋白
|
|
SG10201913324PA
(en)
|
2014-05-29 |
2020-03-30 |
Macrogenics Inc |
Tri-specific binding molecules and methods of use thereof
|
|
JP6702893B2
(ja)
|
2014-06-27 |
2020-06-03 |
イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． |
多重特異的抗原結合タンパク質
|
|
AU2015279316B2
(en)
|
2014-06-27 |
2021-03-04 |
Innate Pharma |
Multispecific NKp46 binding proteins
|
|
JP6526189B2
(ja)
|
2014-07-03 |
2019-06-05 |
ベイジーン リミテッド |
抗ｐｄ−ｌ１抗体並びにその治療及び診断のための使用
|
|
CA2955984A1
(en)
|
2014-07-22 |
2016-01-28 |
The University Of Notre Dame Du Lac |
Molecular constructs and uses thereof
|
|
EP3171892B1
(en)
|
2014-07-22 |
2021-11-24 |
Apollomics Inc. |
Anti-pd-1 antibodies
|
|
RU2722212C9
(ru)
|
2014-08-05 |
2020-07-23 |
СиБи ТЕРЕПЬЮТИКС, ИНК. |
Анти-pd-l1 антитела
|
|
GB201413913D0
(en)
|
2014-08-06 |
2014-09-17 |
Cantargia Ab |
Novel antibodies and uses thereof
|
|
WO2016030488A1
(en)
|
2014-08-27 |
2016-03-03 |
Innate Pharma |
Treatment of celiac disease
|
|
SG11201702544WA
(en)
|
2014-09-29 |
2017-04-27 |
Univ Duke |
Bispecific molecules comprising an hiv-1 envelope targeting arm
|
|
EP3659625A1
(en)
|
2014-10-23 |
2020-06-03 |
Innate Pharma |
Treatment of cancers using anti-nkg2a agents
|
|
KR20170076697A
(ko)
*
|
2014-11-06 |
2017-07-04 |
에프. 호프만-라 로슈 아게 |
개질된 FCRN-결합 특성 및 단백질 A-결합 특성을 가진 Fc-영역 변이체
|
|
PT3221359T
(pt)
|
2014-11-17 |
2020-06-23 |
Regeneron Pharma |
Métodos para o tratamento de tumores usando anticorpos biespecíficos cd3xcd20
|
|
EP3233907B1
(en)
*
|
2014-12-19 |
2021-03-03 |
Genmab A/S |
Rodent bispecific heterodimeric proteins
|
|
IL278014B2
(en)
|
2014-12-19 |
2023-10-01 |
Chugai Pharmaceutical Co Ltd |
Anti-myostatin antibodies, polypeptides containing variable FC regions and methods of use
|
|
SG10201907215QA
(en)
|
2015-02-05 |
2019-09-27 |
Chugai Pharmaceutical Co Ltd |
Antibodies Comprising An Ion Concentration Dependent Antigen-Binding Domain, Fc Region Variants, Il-8-Binding Antibodies, And Uses Therof
|
|
AU2016219511B2
(en)
*
|
2015-02-09 |
2020-11-12 |
Research Development Foundation |
Engineered immunoglobulin Fc polypeptides displaying improved complement activation
|
|
US11071783B2
(en)
|
2015-03-19 |
2021-07-27 |
Duke University |
HIV-1 neutralizing antibodies and uses thereof
|
|
CA2979708A1
(en)
|
2015-03-19 |
2016-09-22 |
Duke University |
Hiv-1 neutralizing antibodies and uses thereof
|
|
US10344077B2
(en)
|
2015-03-19 |
2019-07-09 |
Duke University |
HIV-1 neutralizing antibodies and uses thereof (V3 antibodies)
|
|
WO2016149695A1
(en)
|
2015-03-19 |
2016-09-22 |
Duke University |
HIV-1 NEUTRALIZING ANTIBODIES AND USES THEREOF (CD4bs ANTIBODIES)
|
|
JP6773679B2
(ja)
|
2015-03-30 |
2020-10-21 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
Ｆｃガンマ受容体に対する結合が低下した重鎖定常領域
|
|
TWI773646B
(zh)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
|
TWI870335B
(zh)
|
2015-06-12 |
2025-01-21 |
美商宏觀基因股份有限公司 |
變異的嵌合4d5抗體及其與抗pd-1抗體聯合用於治療癌症的應用
|
|
DK3313876T3
(da)
|
2015-06-23 |
2025-04-22 |
Innate Pharma |
Multispecifikke antigenbindende proteiner
|
|
EP3313881A1
(en)
|
2015-06-23 |
2018-05-02 |
Innate Pharma |
Multispecific nk engager proteins
|
|
SI3328419T1
(sl)
|
2015-07-30 |
2021-11-30 |
Macrogenics, Inc. |
PD-1-vezavne molekule in postopki uporabe le-teh
|
|
RU2731202C2
(ru)
|
2015-10-08 |
2020-08-31 |
Макродженикс, Инк. |
Комбинированная терапия для лечения рака
|
|
AU2016370376B2
(en)
|
2015-12-14 |
2023-12-14 |
Macrogenics, Inc. |
Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof
|
|
EP3394098A4
(en)
|
2015-12-25 |
2019-11-13 |
Chugai Seiyaku Kabushiki Kaisha |
ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE
|
|
KR20180118673A
(ko)
|
2016-03-15 |
2018-10-31 |
이나뜨 파르마 |
항-mica 항체
|
|
US10961311B2
(en)
|
2016-04-15 |
2021-03-30 |
Macrogenics, Inc. |
B7-H3 binding molecules, antibody drug conjugates thereof and methods of use thereof
|
|
JP2019515677A
(ja)
|
2016-04-26 |
2019-06-13 |
アール．ピー．シェーラー テクノロジーズ エルエルシー |
抗体複合体ならびにそれを作製および使用する方法
|
|
CN109475536B
(zh)
|
2016-07-05 |
2022-05-27 |
百济神州有限公司 |
用于治疗癌症的PD-l拮抗剂和RAF抑制剂的组合
|
|
CN109689099B
(zh)
|
2016-08-05 |
2023-02-28 |
中外制药株式会社 |
用于预防或治疗il-8相关疾病的组合物
|
|
CN118252927A
(zh)
|
2016-08-19 |
2024-06-28 |
百济神州有限公司 |
使用包含btk抑制剂的组合产品治疗癌症
|
|
KR102644544B1
(ko)
|
2016-09-21 |
2024-03-11 |
넥스트큐어 인코포레이티드 |
Siglec-15를 위한 항체 및 이의 사용 방법
|
|
EP4360714A3
(en)
|
2016-09-21 |
2024-07-24 |
Nextcure, Inc. |
Antibodies for siglec-15 and methods of use thereof
|
|
MA46534A
(fr)
|
2016-10-14 |
2019-08-21 |
Xencor Inc |
Protéines de fusion fc hétérodimères il15/il15r
|
|
KR20230173745A
(ko)
|
2016-10-21 |
2023-12-27 |
이나뜨 파르마 에스.에이. |
항-kir3dl2 작용제에 의한 치료
|
|
GB201619652D0
(en)
|
2016-11-21 |
2017-01-04 |
Alligator Bioscience Ab |
Novel polypeptides
|
|
KR101872455B1
(ko)
*
|
2016-11-30 |
2018-06-28 |
국민대학교 산학협력단 |
신규한 돌연변이를 포함하는 항체 Ｆｃ 영역
|
|
WO2018104893A1
(en)
|
2016-12-06 |
2018-06-14 |
Glaxosmithkline Intellectual Property Development Limited |
Alpha4-beta7 antibodies with incrased fcrn binding and/or half-life
|
|
US20190322767A1
(en)
|
2016-12-23 |
2019-10-24 |
Innate Pharma |
Heterodimeric antigen binding proteins
|
|
WO2018137681A1
(en)
|
2017-01-25 |
2018-08-02 |
Beigene, Ltd. |
Crystalline forms of (s) -7- (1- (but-2-ynoyl) piperidin-4-yl) -2- (4-phenoxyphenyl) -4, 5, 6, 7-tetrahy dropyrazolo [1, 5-a] pyrimidine-3-carboxamide, preparation, and uses thereof
|
|
CA3052837A1
(en)
|
2017-02-28 |
2018-09-07 |
Seattle Genetics, Inc. |
Cysteine mutated antibodies for conjugation
|
|
CN113480655B
(zh)
|
2017-03-28 |
2022-05-31 |
礼进生物医药科技（上海）有限公司 |
用于增强肿瘤微环境中免疫应答的治疗剂和方法
|
|
US10767164B2
(en)
|
2017-03-30 |
2020-09-08 |
The Research Foundation For The State University Of New York |
Microenvironments for self-assembly of islet organoids from stem cells differentiation
|
|
WO2018196782A1
(en)
|
2017-04-27 |
2018-11-01 |
The University Of Hong Kong |
Use of hcn inhibitors for treatment of cancer
|
|
JP2020525411A
(ja)
|
2017-06-26 |
2020-08-27 |
ベイジーン リミテッド |
肝細胞癌のための免疫療法
|
|
WO2019006472A1
(en)
|
2017-06-30 |
2019-01-03 |
Xencor, Inc. |
TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS
|
|
US11634488B2
(en)
|
2017-07-10 |
2023-04-25 |
International—Drug—Development—Biotech |
Treatment of B cell malignancies using afucosylated pro-apoptotic anti-CD19 antibodies in combination with anti CD20 antibodies or chemotherapeutics
|
|
EP3679070A1
(en)
|
2017-09-07 |
2020-07-15 |
Augusta University Research Institute, Inc. |
Antibodies to programmed cell death protein 1
|
|
EP4640703A2
(en)
|
2017-11-14 |
2025-10-29 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-c1s antibodies and methods of use
|
|
US20200325232A1
(en)
|
2017-11-21 |
2020-10-15 |
Innate Pharma |
Multispecific antigen binding proteins
|
|
WO2019108795A1
(en)
|
2017-11-29 |
2019-06-06 |
Beigene Switzerland Gmbh |
Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors
|
|
US11773171B2
(en)
|
2017-12-19 |
2023-10-03 |
Surrozen Operating, Inc. |
WNT surrogate molecules and uses thereof
|
|
EP4603508A3
(en)
|
2017-12-19 |
2025-10-29 |
Surrozen Operating, Inc. |
Anti-frizzled antibodies and methods of use
|
|
CN111699003B
(zh)
|
2017-12-19 |
2024-05-03 |
瑟罗泽恩奥普瑞汀公司 |
抗lrp5/6抗体和使用方法
|
|
US11078283B2
(en)
|
2018-01-17 |
2021-08-03 |
Apexigen, Inc. |
Anti-PD-L1 antibodies and methods of use
|
|
US20210002373A1
(en)
|
2018-03-01 |
2021-01-07 |
Nextcure, Inc. |
KLRG1 Binding Compositions and Methods of Use Thereof
|
|
JP7351845B2
(ja)
|
2018-03-23 |
2023-09-27 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｍｉｃａおよび／またはｍｉｃｂに対する抗体ならびにそれらの使用
|
|
CA3097741A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
|
|
SG11202010159RA
(en)
|
2018-04-18 |
2020-11-27 |
Xencor Inc |
Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof
|
|
MX2020010910A
(es)
|
2018-04-18 |
2021-02-09 |
Xencor Inc |
Proteinas de fusion heterodimericas dirigidas a pd-1 que contienen proteinas de fusion il-15 / il-15ra fc y dominios de union al antigeno pd-1 y usos de los mismos.
|
|
WO2020010308A1
(en)
|
2018-07-05 |
2020-01-09 |
Surrozen, Inc. |
Multi-specific wnt surrogate molecules and uses thereof
|
|
MX2021001431A
(es)
|
2018-08-10 |
2021-05-12 |
Chugai Pharmaceutical Co Ltd |
Molecula de union al antigeno anti grupo de diferenciacion 137 (cd137) y su uso.
|
|
IL280875B2
(en)
|
2018-08-31 |
2024-12-01 |
Regeneron Pharma |
Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies
|
|
US12331320B2
(en)
|
2018-10-10 |
2025-06-17 |
The Research Foundation For The State University Of New York |
Genome edited cancer cell vaccines
|
|
MA53862A
(fr)
|
2018-10-12 |
2022-01-19 |
Xencor Inc |
Protéines de fusion fc d'il-15/il-15ralpha ciblant pd-1 et utilisations dans des polythérapies faisant intervenir celles-ci
|
|
WO2020118293A2
(en)
|
2018-12-07 |
2020-06-11 |
Georgia Tech Research Corporation |
Antibodies that bind to natively folded myocilin
|
|
TWI874341B
(zh)
|
2018-12-18 |
2025-03-01 |
美商健生生物科技公司 |
產生異二聚體抗體之方法
|
|
EP3897853A1
(en)
|
2018-12-20 |
2021-10-27 |
Xencor, Inc. |
Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and nkg2d antigen binding domains
|
|
AU2020210710A1
(en)
|
2019-01-22 |
2021-07-29 |
Innate Pharma |
Treatment of T cell lymphoma
|
|
CN113874392B
(zh)
|
2019-03-28 |
2025-10-21 |
丹尼斯科美国公司 |
工程化抗体
|
|
KR20220016865A9
(ko)
|
2019-05-15 |
2022-02-21 |
추가이 세이야쿠 가부시키가이샤 |
항원 결합 분자, 약학 조성물, 및 방법
|
|
TW202126335A
(zh)
|
2019-08-07 |
2021-07-16 |
美商樂天醫藥生技股份有限公司 |
西妥昔單抗(cetuximab)-ir700結合物組合物
|
|
TW202128757A
(zh)
|
2019-10-11 |
2021-08-01 |
美商建南德克公司 |
具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
|
|
US11897950B2
(en)
|
2019-12-06 |
2024-02-13 |
Augusta University Research Institute, Inc. |
Osteopontin monoclonal antibodies
|
|
WO2021146383A1
(en)
|
2020-01-17 |
2021-07-22 |
BioLegend, Inc. |
Anti-tlr7 agents and compositions and methods for making and using the same
|
|
US20230203191A1
(en)
|
2020-03-30 |
2023-06-29 |
Danisco Us Inc |
Engineered antibodies
|
|
GB2595299B
(en)
|
2020-05-21 |
2022-08-03 |
Mabsolve Ltd |
Modified immunoglobulin FC regions
|
|
WO2022093641A1
(en)
|
2020-10-30 |
2022-05-05 |
BioLegend, Inc. |
Anti-nkg2a agents and compositions and methods for making and using the same
|
|
WO2022093640A1
(en)
|
2020-10-30 |
2022-05-05 |
BioLegend, Inc. |
Anti-nkg2c agents and compositions and methods for making and using the same
|
|
KR20230109668A
(ko)
|
2020-11-16 |
2023-07-20 |
서로젠 오퍼레이팅, 인크. |
간-특이적 Wnt 신호 증강 분자 및 그의 용도
|
|
JP2024500920A
(ja)
|
2020-12-23 |
2024-01-10 |
カンタージア アクチエボラーグ |
抗ｉｌ１ｒａｐ抗体
|
|
IL305847A
(en)
|
2021-03-26 |
2023-11-01 |
Innate Pharma |
Multispecific proteins that contain a binding site for NKP46, a binding site for a cancer antigen that is fused to a cytokine to attract NK cells
|
|
WO2022258678A1
(en)
|
2021-06-09 |
2022-12-15 |
Innate Pharma |
Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
|
|
US20250002601A1
(en)
|
2021-06-09 |
2025-01-02 |
Innate Pharma |
Multispecific antibodies binding to cd20, nkp46, cd16 and conjugated to il-2
|
|
WO2022258691A1
(en)
|
2021-06-09 |
2022-12-15 |
Innate Pharma |
Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
|
|
WO2022258662A1
(en)
|
2021-06-09 |
2022-12-15 |
Innate Pharma |
Multispecific proteins binding to nkp46, a cytokine receptor, a tumour antigen and cd16a
|
|
US12448451B2
(en)
|
2021-06-25 |
2025-10-21 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-CTLA-4 antibody and use thereof
|
|
JP2024527977A
(ja)
|
2021-07-27 |
2024-07-26 |
ノヴァブ， インコーポレイテッド |
免疫エフェクター機能を有する操作されたｖｌｒｂ抗体
|
|
US12467921B2
(en)
|
2021-08-31 |
2025-11-11 |
Versitech Limited |
Antibodies and assays for detection of Burkholderia mallei
|
|
KR102828032B1
(ko)
*
|
2021-09-17 |
2025-07-01 |
고려대학교 산학협력단 |
Fc 감마 수용체와의 결합력이 증대된 Fc 변이체
|
|
US20240336665A1
(en)
*
|
2021-11-08 |
2024-10-10 |
Acroimmune Guangzhou Biotech Ltd |
Fusion proteins comprising 072 core peptide and use thereof
|
|
AU2023212994A1
(en)
|
2022-01-28 |
2024-08-08 |
Georgiamune Inc. |
Antibodies to programmed cell death protein 1 that are pd-1 agonists
|
|
WO2023240124A1
(en)
|
2022-06-07 |
2023-12-14 |
Regeneron Pharmaceuticals, Inc. |
Pseudotyped viral particles for targeting tcr-expressing cells
|
|
JP2025519477A
(ja)
|
2022-06-07 |
2025-06-26 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Ｔ細胞活性を調節するための多重特異性分子及びその使用
|
|
CN119301155A
(zh)
|
2022-07-19 |
2025-01-10 |
百进生物科技公司 |
抗cd157抗体、其抗原结合片段和组合物及其制备和使用方法
|
|
WO2024040114A2
(en)
|
2022-08-18 |
2024-02-22 |
BioLegend, Inc. |
Anti-axl antibodies, antigen-binding fragments thereof and methods for making and using the same
|
|
JP2025529210A
(ja)
|
2022-09-01 |
2025-09-04 |
ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド |
アポリポタンパク質ｌ１を導いて哺乳動物の細胞死を誘導するための組成物及び方法
|
|
EP4608515A1
(en)
|
2022-10-25 |
2025-09-03 |
Seismic Therapeutic, Inc. |
Variant igg fc polypeptides and uses thereof
|
|
KR20250167153A
(ko)
|
2023-03-03 |
2025-11-28 |
셀덱스 쎄라퓨틱스, 인크. |
항-줄기 세포 인자(scf) 및 항-흉선 기질 림포포이에틴(tslp) 항체, 및 이중특이적 구축물
|
|
AU2024270136A1
(en)
|
2023-05-05 |
2025-11-20 |
Otsuka Pharmaceutical Co., Ltd. |
Anti-il1rap antibodies
|
|
WO2024243217A1
(en)
|
2023-05-25 |
2024-11-28 |
BioLegend, Inc. |
Ceacam6 binding antibodies and antigen-binding fragments thereof
|
|
WO2024251884A1
(en)
|
2023-06-09 |
2024-12-12 |
Innate Pharma |
Nk cell engager proteins comprising anti-cd20 and ant-nkp46 antibody, linked to il-2 in treatment of r/r b-nhl
|